The US Food and Drug Administration (FDA) recently approved donislecel, marketed by CellTrans Inc as Lantidra, for the treatment of type 1 diabetes in adults who experience repeated episodes of severe low blood glucose levels. The treatment involves the infusion of insulin-producing pancreatic islet beta cells from deceased donors into patients’ hepatic portal veins and immunosuppressive medication to maintain islet cell viability.
Source: JAMA Online First